NEXGEL, INC.

NexGel, Inc. announced on June 17, 2026, that it has started using a new investor presentation. This presentation provides updated information for investors and is furnished as Exhibit 99.1 to the company's current report on Form 8-K.

NexGel, Inc. will hold its 2026 Annual Meeting of Stockholders on July 10, 2026, to vote on several key proposals. These include the reincorporation from Delaware to Nevada, which encompasses an increase in authorized common stock to 100,000,000 shares and a discretionary reverse stock split (1-for-2 to 1-for-10). Stockholders will also vote on approving the issuance of over 19.99% of outstanding common stock for recent private placements to comply with Nasdaq rules. Other proposals cover the election of seven directors, an advisory vote on executive compensation, and the ratification of the independent auditor.

NEXGEL, Inc. announced that its Chief Executive Officer, Adam Levy, will present at the Planet MicroCap Conference in Las Vegas, NV. The presentation is scheduled for June 17, 2026, at 1:30 P.M. PT. The company will also have a booth at the conference, which runs from June 16-18, 2026, and investors can schedule one-on-one meetings with Mr. Levy.

NEXGEL, Inc. completed a private placement between May 11-14, 2026, raising $1.21 million in gross proceeds. The offering included unsecured convertible promissory notes totaling $1.21 million and warrants to purchase 1,008,334 shares of common stock. The company intends to use the net proceeds for working capital. Affiliates, including directors and the CEO, purchased $1.085 million of the securities, and a registration rights agreement was executed.

NexGel, Inc. acquired Celularity Inc.'s regenerative biomaterials portfolio and development programs for $13.3 million, including $8.3 million cash and a $5 million convertible note. Concurrently, the company raised $8.585 million through private placements of convertible notes and warrants in April and May 2026. For Q1 2026, NexGel reported a net loss of $927,000 on $2.65 million in revenue, compared to a $712,000 net loss on $2.806 million revenue in Q1 2025. The company noted substantial doubt about its ability to continue as a going concern, with the new acquisition expected to improve liquidity.

NEXGEL, Inc. announced the appointment of Brian J. Kieser and Kevin M. Harris to its Board of Directors on May 6, 2026. Both appointees are executives at Sequence LifeScience, which recently led a $5.5 million strategic investment to finance NEXGEL's acquisition of assets and licenses from Celularity Inc. Additionally, Mr. Kieser made a personal investment of $1 million in NEXGEL through a convertible promissory note and warrant.

NEXGEL, Inc. announced it will report its financial results for the first quarter ended March 31, 2026, on Friday, May 15, 2026. Following the release of its financial results, the company will host a conference call at 12:00 P.M. ET on the same day. A replay of the call will be available for interested individuals unable to join the live conference.

NEXGEL, Inc. announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to its Board of Directors. Mr. Kieser and Mr. Harris are the CEO and COO of Sequence LifeScienceTM, which recently led the financing to close on NEXGEL's acquisition of Celularity Inc.’s degenerative disease segment with a $5.5 million strategic investment. This move strengthens the partnership between NEXGEL and Sequence LifeScienceTM, bringing valuable industry experience and distribution capabilities to support NEXGEL's growth and expansion following the acquisition.

NEXGEL, INC. filed an amendment to its Form 10-K to include previously omitted Part III information, detailing corporate governance, executive compensation, and security ownership. The amendment highlights the appointment of Ian Blackman as Chief Financial Officer, effective April 27, 2026, replacing Adam E. Drapczuk III. The filing also provides comprehensive information on the company's board of directors, executive compensation for 2024 and 2025, and various corporate governance policies.

NEXGEL, Inc. announced the appointment of Ian Blackman, 58, as its new Chief Financial Officer, effective April 27, 2026. Mr. Blackman, a Certified Public Accountant with over 30 years of global financial leadership experience, succeeds Mr. Drapczuk. His appointment is aimed at advancing the integration of the Celularity acquisition, scaling the business, and accelerating growth. His compensation package includes a $250,000 annual base salary, performance-based cash bonuses up to 50% of his base salary for fiscal year 2026, and an initial grant of options to purchase 160,000 shares of common stock.